Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

FOLD – Amicus Therapeutics, Inc.

Float Short %

7.21

Margin Of Safety %

Put/Call OI Ratio

0.55

EPS Next Q Diff

0.22

EPS Last/This Y

0.5

EPS This/Next Y

0.36

Price

7.61

Target Price

16.09

Analyst Recom

1.33

Performance Q

21.57

Relative Volume

0.84

Beta

0.52

Ticker: FOLD




20 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-07-28FOLD6.120.590.0713424
2025-07-29FOLD6.140.590.0013472
2025-07-30FOLD6.120.590.0113475
2025-07-31FOLD5.990.560.2413422
2025-08-01FOLD6.320.550.1613579
2025-08-04FOLD6.840.550.0613617
2025-08-05FOLD6.990.520.0014252
2025-08-06FOLD6.930.520.9314257
2025-08-07FOLD6.80.540.0014406
2025-08-08FOLD6.770.530.0014622
2025-08-11FOLD6.660.530.2514654
2025-08-12FOLD6.970.530.0014657
2025-08-13FOLD7.20.530.7614668
2025-08-14FOLD7.110.570.1116717
2025-08-15FOLD7.410.580.0316707
2025-08-18FOLD7.410.590.1016273
2025-08-19FOLD7.330.590.0016251
2025-08-20FOLD7.390.600.0116241
2025-08-21FOLD7.610.550.8617059
2025-08-22FOLD7.610.550.0017156
DateSymbolLastP/C OIP/C VolTotal OI
20 items Current Page1 of 1




20 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-07-28FOLD6.12-71.4-0.10.32
2025-07-29FOLD6.13-71.4-0.50.32
2025-07-30FOLD6.13-71.4-0.60.32
2025-07-31FOLD5.99-71.4-1.50.32
2025-08-01FOLD6.32-71.41.70.32
2025-08-04FOLD6.8317.223.00.32
2025-08-05FOLD6.9917.220.60.32
2025-08-06FOLD6.9322.444.70.32
2025-08-07FOLD6.7922.444.00.32
2025-08-08FOLD6.7622.445.00.32
2025-08-11FOLD6.6622.444.30.32
2025-08-12FOLD6.9822.448.30.32
2025-08-13FOLD7.1922.447.20.32
2025-08-14FOLD7.1122.444.60.32
2025-08-15FOLD7.4122.447.90.32
2025-08-18FOLD7.4122.445.40.32
2025-08-19FOLD7.3422.444.70.32
2025-08-20FOLD7.4022.445.80.32
2025-08-21FOLD7.6122.447.10.32
2025-08-22FOLD7.6122.445.30.32
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
20 items Current Page1 of 1




20 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-07-28FOLD-0.004.197.31
2025-07-29FOLD-0.004.197.31
2025-07-30FOLD-0.004.197.31
2025-07-31FOLD-0.004.197.31
2025-08-01FOLD-0.004.197.31
2025-08-04FOLD-0.003.937.31
2025-08-05FOLD-0.003.937.31
2025-08-06FOLD-0.003.937.31
2025-08-07FOLD-0.003.937.31
2025-08-08FOLD-0.003.937.31
2025-08-11FOLD-0.003.717.31
2025-08-12FOLD-0.003.717.28
2025-08-13FOLD-0.003.717.28
2025-08-14FOLD-0.003.717.28
2025-08-15FOLD-0.003.717.28
2025-08-18FOLD-0.006.177.21
2025-08-19FOLD-0.006.177.21
2025-08-20FOLD-0.006.177.21
2025-08-21FOLD-0.006.177.21
2025-08-22FOLD0.006.177.21
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
20 items Current Page1 of 1

Last Quarter Act. EPS

-0.05

Avg. EPS Est. Current Quarter

0.12

Avg. EPS Est. Next Quarter

0.17

Insider Transactions

Institutional Transactions

6.17

Beta

0.52

Average Sales Estimate Current Quarter

165

Average Sales Estimate Next Quarter

181

Fair Value

Quality Score

53

Growth Score

51

Sentiment Score

60

Actual DrawDown %

70

Max Drawdown 5-Year %

-77.3

Target Price

16.09

P/E

Forward P/E

26.98

PEG

P/S

4.11

P/B

11.47

P/Free Cash Flow

EPS

-0.12

Average EPS Est. Cur. Y​

0.32

EPS Next Y. (Est.)

0.68

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-6.67

Relative Volume

0.84

Return on Equity vs Sector %

-43.3

Return on Equity vs Industry %

-30.4

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

45.3
Amicus Therapeutics, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 499
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally. The company's commercial product and product candidates consist of Galafold, an orally administered monotherapy for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, a novel two-component treatment program for adults living with late-onset Pompe disease. It has collaboration and license agreement with GlaxoSmithKline to develop and commercialize Galafold. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.
stock quote shares FOLD – Amicus Therapeutics, Inc. Stock Price stock today
news today FOLD – Amicus Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch FOLD – Amicus Therapeutics, Inc. yahoo finance google finance
stock history FOLD – Amicus Therapeutics, Inc. invest stock market
stock prices FOLD premarket after hours
ticker FOLD fair value insiders trading